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The Peanut Allergy Epidemic
Rivky Sachs

ABSTRACT
Peanut allergy is one of the most predominant food allergies. It accounts for
majority of the highly severe and fatal allergic reactions to food. Peanut allergy is generally
detected early in life and is commonly associated with other atopic disorders such as asthma,
eczema, and rhinitis. The prevalence and pervasiveness of peanut allergies is increasing
worldwide, and most peanut allergic patients have lifelong sensitivities to peanuts (de Leon et al,
2008).
Patients with severe allergies must stringently avoid any contact with peanuts and depend
on intramuscular epinephrine (EpiPen) to counteract the reaction caused by intake of peanuts.
Much research is dedicated to developing new treatments that may be able to induce tolerance in
peanut allergic individuals without adverse side effects. This paper reviews the current
understanding of clinical characteristics, pathogenesis, and hypothetical causes for the rise in
prevalence of peanut allergies. It also discusses genetic risks and environmental effects of peanut
allergy. Furthermore, it presents emergent future therapies and methods to prevent the
development of peanut allergies in infants.
INTODUCTION
Allergy is defined as an adverse immune response to food (Sicherer and Sampson, 2010).
Such responses can be mediated by IgE antibodies aimed at specific allergens, or they can be
triggered by other cellular activities (Wood, 2009). IgE mediated reactions are immediate, and
symptoms can range from acute or chronic atopic reactions to fatal anaphylaxis. Non- IgE
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mediated allergy occurs gradually and is evident by chronic skin conditions and gastrointestinal
discomfort (Eigenmann, 2009). Peanut allergy is an IgE mediated response.
EXPOSURE TO THE FOOD ALLERGEN
Peanut allergens are introduced to the body through one of three particular ways:
ingestion, skin contact, or inhalation of airborne particles. In the most prevalent form of the
allergy, peanuts must be consumed for an allergic reaction to ensue since the allergic reaction is
not frequently activated by skin or air contact with the peanut allergen. Food enters the digestive
system through the mouth and the food allergen is first introduced at the mucosal surface of the
gastrointestinal tract (Burks, 2008).
PATHOGENESIS
At the mucosal surface of the gut, food proteins are digested by specialized epithelial
cells that transfer them to antigen presenting cells such as dendritic cells which then process
them into peptide fragments. These peptide fragments are presented on the cell surface by class
II major histocompatibility complex (MHC) molecules. As the antigen presenting cell presents
the antigen to T helper cells through MHC/T cell receptor interaction it activates the T helper
cells. This process instigates humoral and cellular mediated responses that are associated with
peanut allergy (de Leon et al, 2008).
In peanut allergic individuals, the activation of T helper 2 (TH2) cells causes the
production of cytokines such as interleukins including IL-4, IL-5, IL-9, and IL-13. These
interleukins are released in increased amounts as compared to individuals that are not allergic to
peanuts, thus exciting B cells to synthesize IgE antibodies. These peanut specific IgE antibodies
are attached to mast cells in the gastrointestinal tract mucosa, skin, and respiratory tract mucosa
and to basophils (Burks, 2003, Burks, 2008).
Upon ingestion of peanuts, the peanut proteins bind with the specific IgE antibodies on
mast cells and basophils thereby secreting inflammatory mediators such as histamine. TH2 cells
and mast cells also produce tumour necrosis factor- a (TNF-a), IL-5, and chemokines, which
cause eosiniphils to accumulate at the site inflammation. Eosiniphils stimulate the release of
other inflammatory mediators which lead to clinical symptoms that will immediately develop (de
Leon et al, 2008).
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Allergic reaction to peanut (Burks, 2008)
CLINICAL SYMPTOMS
Clinical symptoms can be triggered by ingesting ten milligrams of peanut protein. The
time it takes for symptoms to develop ranges from seconds up to two hours after ingestion. The
majority of reactions of IgE mediated disorders include skin, respiratory, and gastrointestinal
symptoms. Local symptoms include itching, swelling, nausea, vomiting, cramping, and diarrhea
(Burks, 2008).
Anaphylaxis, a systemic symptom, can often be fatal. The early symptoms of anaphylaxis
include oral and pharyngeal pruritus and chest tightness. Further symptoms of wheezing,
hypotension, arrythema, and unconsciousness can develop into fatal and near fatal reactions (Lee
et al, 2003). Anaphylaxis is a rapidly progressing multiple organ system reaction that can lead to
cardiovascular failure. This reaction is a result of a massive release of mediators such as
histamine (Sicherer and Sampson, 2010).
EPIDEMIOLOGY AND RISING PREVALENCE
Studies done in the United Kingdom and North America show peanut allergy prevalence
rates in children have increased, in fact, almost doubling. Peanut allergy affects more than 1% of
school aged children (Sicherer and Sampson, 2007). Grundy et al did two sequential cohorts in
the Isle of Wight, United Kingdom six years apart. Children at the age of 3 and 4 received skin
prick tests and those with positive results were given oral peanut challenges unless there was an
otherwise convincing history of peanut allergy. The study confirmed an increase in peanut
allergy from .5% to 1.0% between 1989 and 1995.
The same incidence was reported in the U.S. with rates similar to those received in the
previous study. In 1997, Sicherer, Munoz-Furlong, and Sampson performed a population based,
cross-sectional, random telephone survey in the United States using a standardized questionnaire.
In 2003, they conducted a five year follow up study to compare the results of the prevalence
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estimates. The study indicated a doubling in peanut allergy in children from 0.4% in 1997 to
0.8% in 2002.
Kagan and colleagues also confirmed the assumption of increasing prevalence of peanut
allergy using diagnostic testing. They assigned questionnaires regarding peanut ingestion to
parents of children in kindergarten through grade 3 in randomly selected schools in Montreal.
Respondents were grouped as follows: (1) peanut tolerant, (2) never-rarely ingest peanut, (3)
convincing history of peanut allergy, and (4) uncertain history of peanut allergy.
Groups 2, 3, and 4 received peanut skin prick tests (SPTs), and if responses in groups 2
and 4 were positive, measurement of peanut specific IgE was taken. Children in group 3 with a
positive SPT were considered to have peanut allergy without more testing. Children in groups 2
and 4 who had peanut specific IgE levels less than 15kU/L were administered oral peanut
challenges. These techniques ensured that only children who had real peanut allergic symptoms
were considered sensitive. Their estimate of 1.5% proves that the prevalence of peanut allergy
was even higher than what had previously been reported (Kagan et al, 2003).
However, five years later a follow up study was performed using the same methodology
and population to determine whether prevalence was increasing over time. The prevalence
estimate was 1.62%, indicating a .13% difference. They concluded that the prevalence has
remained stable among this population. Furthermore, they refuted the studies conducted by
Grundy et al and Sicherer et al by saying that the increasing prevalence estimates they reported
was a result of environmental changes during the period that they experimented and that
participation rates were lower at follow up, thus leading to an overestimate of prevalence. Also,
they claim that the .4% difference in estimates of the case study done by Sicherer et al is not
statistically significant (Ben Shoshan, et al 2003).
There are numerous problems with this follow up study done in Montreal and the
conclusions drawn from its results. This study was conducted in one small region with low
participation rates, as compared to the survey performed by Sicherer et al which covered the
entire United States with a census of over 13,000 individuals. Therefore, .4% estimate is in
actuality a large percentage of the population.
Moreover, they base their estimates on the assumption that peanut specific IgE levels of
15kU/L or greater indicate a peanut allergy. Consequently, they only presented peanut oral
challenges to children who had positive SPTs with less than 15kU/L peanut specific IgE levels;
even though there is no proof that a positive peanut specific IgE level implies that an individual
does indeed have a peanut allergy. According to recent studies, between 50% and 75% of
patients with specific IgE to food are not allergic to the food (Roberts et al 2005). On the
contrary, in the study done by Grundy et al, all children with positive skin prick tests, not
including those with a history of peanut allergy, underwent oral challenges regardless of their
peanut specific IgE level. They did not rely on peanut specific IgE levels to determine if the child
has a peanut allergy. Due to this and many other incorrect assumptions, this study loses its
credibility. In addition, their criticism and disapproval of other studies is inherently biased and
lacks evidence.
Over the past twenty years there has been a universal increase in children being
diagnosed with this allergy (Grundy et al, 2002). The rise in prevalence of peanut allergies has
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initiated much research in this field. There are numerous new hypotheses and theories to explain
the apparent peanut epidemic.
SPECIFIC PEANUT ALLERGENS
Antigens that involve an IgE response are referred to as allergens, which are the
glycoproteins found in food. Eight peanut allergens have been discovered and are classified as
Ara h 1 to Ara h 8 (Burks 2008). The three major peanut allergens are Ara h 1, Ara h 2, and Ara
h 3. Ara h 1 and Ara h 2 are known to be highly allergenic, because numerous peanut allergic
individuals have serum specific IgE for these allergens.
The classification of Ara h 3 has not yet been identified: one study showed serum IgE
reactivity in 44% of peanut allergic subjects while another found it in 95% of the patients. Ara h
4-7 are not as reactive with IgE in patient sera and have not yet been classified. Ara h 8 is
different than the others as it is established to be a major allergen in Central Europe in
individuals who display a co-allergy to peanut and birch pollen (de Leon et al, 2008).
BIOCHEMICAL PROPERTIES OF PEANUT ALLERGENS
According to Koppelman et al, many peanut allergens have specific physiochemical
properties that display resistance to digestive enzymes and heat processing. Their study proves
that Ara h1 is heat stable, although its structure is changed significantly when heated. The
resistance of some peanut allergens to heat and enzymes may be connected to their ability of
forming stable dimer and trimer complexes. This enables the peanut proteins to reach the
intestinal mucosa intact, thus increasing their allergenicity and effectiveness.

MAILLARD REACTION
A major reaction that happens during the browning or processing of foods is the Maillard
reaction. One of the main chemical modifications that peanut proteins undergo is the Maillard
reaction which reduces sugars and primary amine groups thus increasing the allergic properties
of peanuts. Maleki, Chung, Champagne, and Raufman proved this by conducting an in vitro
model copying the Maillard reaction. Ara h 1 heated in the presence of sugars exhibited
increased allergenicity, while Ara h 1 heated without sugars degraded and was barely
discernible. Roasted peanut extracts were found to bind to IgE serum of allergic individuals at
about 90- fold higher than raw peanuts. The Maillard reaction contributed to this effect. This
study supports the findings of Nordlee et al that roasted peanuts bind IgE at higher levels than
raw peanuts. It also shows that modification of proteins during the roasting process increases the
IgE binding sites and enhances other allergenic properties in peanuts (Maleki et al, 2000).
EFFECTS OF COOKING METHODS ON PEANUT PROTIENS
There is a much lower prevalence of peanut allergy in China than in the United States,
even though there is a higher rate of peanut consumption in China. Peanuts are fried and boiled
in China; whereas they are usually roasted in the U.S. In 2001, Beyer et al conducted a study to
examine whether the method of preparing peanuts could be a contributing factor to the difference
of allergy prevalence between China and the United States. The Chinese-American population
seems to have a similar prevalence of peanut allergy as the general U.S. population, so genes
cannot account for this difference.
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Two kinds of peanuts grown in the United States were roasted, boiled, and fried. Proteins
were examined using SDS-PAGE and immunoblotting. Reactions to the peanuts were compared
by using immunolabeling with sera from 8 individuals with peanut allergy. Frying and boiling
modified the proteins of both types of peanuts in a similar way. The roasted peanuts had more
Ara h1 which resulted in an increase in IgE binding intensity as compared to the boiled and fried
peanuts. Furthermore, in the fried and boiled peanuts there was less IgE binding to Ara h 2 and
Ara h 3 than there was in the roasted peanuts.
Beyer et al concluded that frying and boiling peanuts, as done in China, reduces the
allergenic property of peanuts as compared to the roasting method which is widely used in the
United States. Roasting uses higher temperatures that probably strengthen the allergenicity of
peanut proteins by causing permanent changes in the structure and may account for the
difference in prevalence of peanut allergy in the two countries (Beyer et al, 2001).
Although this study has strong supporting data, the tests performed are statistically
insignificant and do not prove its hypothesis. There were only 8 samples of patient sera taken to
compare the different reactions. This is a very small range with little diversity, and it does not
differentiate between age groups. Recent statistics confirm that there are in fact more children
with peanut allergies in China than what was initially thought (Burks, 2008). This does not
invalidate the studies that show that roasting enhances peanut allergenicity. More information is
needed about the prevalence of peanut allergy to better understand this subject matter.
ARA H 2 FUNCTIONS AS A TRYPSIN INHIBITOR
In their previous study, Maleki et al showed that the allergenicity of peanut proteins is
enhanced due to thermal processing. Because of the increasing prevalence of peanut allergy and
the severity of the symptoms, another study was performed by Maleki and his colleagues to find
out whether any specific functions are associated with the major peanut allergen, Ara h 2, and
whether these functions are affected by processing. Maleki et al conducted a protein domain
homology search to figure out the functions of Ara h 2. Reputed functions were tested via
enzyme assays and protein gel electrophoresis. Afterward, the structural properties of Ara h 2
from purified and roasted peanuts were compared.
According to their results, Ara h 2 purified from peanuts acts as a trypsin (digestive
protein) inhibitor and roasting increases the trypsin inhibitory activity by a 3.6-fold. Ara h 2 was
also found to protect Ara h 1, a second major allergen, from trypsin digestion. This characteristic
was improved in Ara h 2 purified from roasted peanuts.
The data indicates that thermal processing may play a significant role in increased
allergenicity of peanuts. Not only does roasting change the structure and stabilize peanut proteins
as has already been proven, but it also alters its functional properties which further contribute to
its increased allergenicity. Ara h 2 increases its resistance toward and provides Ara h 1 with extra
protection against trypsin digestive enzymes (Maleki et al, 2003).
GENETIC RISK FACTORS OF PEANUT ALLERGY
It is implausible that genetic factors contributed to the increase of peanut allergy in
certain parts of the world over the past decade. Nonetheless, it is probable there are genetic
predisposing factors that contribute to the development of food allergy, just like there are genetic
factors associated with other atopic diseases such as asthma and eczema. More research is
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needed to figure out which genetic polymorphisms are associated with specific allergies (Lack,
2008).
Peanut allergy has been associated with familial inheritance and genetics. Hourihane,
Dean, and Warner calculated rates of other atopic symptoms in people with peanut allergy and
the prevalence of the allergy in their families. They concluded that a child with a peanut allergic
sibling has a 7- fold increase of developing a peanut allergy (Hourihane et al, 1996).
A study was performed by Sicherer et al to determine if genetic factors influence peanut
allergy by comparing the rate of this allergy among monozygotic and dizygotic twins. The
method relies on the fact that monozygotic twins share all of the same genes, while dizygotic
twins share only half of their genes. They found that there was a considerably higher peanut
allergy association among monozygotic twin pairs than there was among dizygotic twin pairs. In
monozygotic twins, a child has a 64.3% chance of developing peanut allergy if his/her twin has
the allergy, while a dizygotic twin has only a 6.8% chance.
This data suggests that specific genes influence the development of peanut allergy in an
individual. However, there are limitations to the results received in Sicherer et al’s study. Firstly,
it was impossible to get a population based sample, because of the low population rate of twins
with peanut allergies. In addition, environmental factors affect gene expression and are also
responsible for the increasing prevalence of peanut allergy.
VITAMIN D HYPTHOSES
The vitamin D hypotheses have been developed to explain the increase of allergies and
asthma, and it involves two opposing studies. One is the vitamin D excess hypothesis which
proposes that increased Vitamin D level results in a higher prevalence of allergies. The vitamin
D deficiency hypothesis argues the opposite. Wjst, the first to work out the vitamin D excess
hypothesis, recognized that in German farming communities there was less vitamin D
supplementation in food and less allergies found in children. The theory was further advanced
when they found an increase in allergies in Bavaria which happened around the same time that
vitamin D supplementations were added to children’s diets to prevent rickets. Milner et al and
Hypponnen et al both performed studies which proved that infants who had vitamin D added to
their diets were at a greater risk for developing food allergies.
Those that support the vitamin D deficiency hypothesis say that people who do not get
enough vitamin D from sunlight have a greater prevalence of allergies. They proved that
countries further from the equator are less exposed to sunlight yet have higher rates of asthma
(Lack, 2008). One intriguing study performed by Camargo et al provides evidence for the
vitamin D deficiency hypothesis. They observed a strong north-south gradient for the
prescription of EpiPens in the United States. In the New England region 8-12 EpiPens per 1000
persons were being distributed, while the southern states had only 3 EpiPen prescriptions per
1000 persons. Their data supports the presumable association between low vitamin D rates and
allergies. There are proofs to substantiate both of these hypotheses, yet the vitamin D
controversy remains unresolved.
ORAL AND NONORAL EXPOSURE TO PEANUT ALLERGEN
Infants can be exposed to peanuts through ingestion or via environmental exposure such
as topical use of peanut derivatives. Other types of exposure can occur in utero or through breast
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milk (de Leon et al, 2007). The exposure route through which sensitization occurs remains
unknown, and there are various schools of thought on this subject (Fox et al, 2009).
PEANUT AVOIDANCE DURING PREGNANCY, LACTATION, AND INFANCY
In order to reduce the prevalence of peanut allergy, the UK health department advised
pregnant or nursing mothers to avoid eating peanut products if they themselves or other
immediate family members of the fetus are atopic (Ewan, 1998). Hourihane et al conducted a
study five years after the UK peanut avoidance advice which showed that the prevalence of
peanut allergy in the UK increased. The authors concluded that the government’s advice showed
no significant influence on the outcome (Hourihane et al, 2007).
Similarly, the American Academy of Pediatrics committee recommended avoiding
peanuts in the infant’s diet during the first three years of life in order to prevent peanut allergy
development (Baker et al, 2000). It was later confirmed that peanut allergy in children doubled
since the recommendation was put into effect (Burks, 2009). However, it still remains tentative
whether peanut avoidance during pregnancy and lactation has a positive, negative or no impact at
all on the prevalence of this allergy in children (Hourihane et al, 2007).
DUAL-ALLERGEN EXPOSURE HYPOTHESIS
Fox et al presented data substantiating a different theory in which low-dose early
environmental exposure increases the probability of developing a peanut allergy as opposed to
maternal consumption of peanuts. Since most children with peanut allergy react on their first oral
exposure to peanut, they hypothesized that cutaneous exposure is the route through which
allergic sensitization occurs. In a previous study, they showed that topical exposure to creams
containing peanut oil was a risk factor for the development of peanut allergy. Almost 91% of the
children with peanut allergy were exposed via use of peanut oil in the first six months of life.
Moreover, in households where peanut is consumed a lot, there are other forms of environmental
exposure that can occur such as cutaneous contact or inhalation of the allergen. For example,
there is always remaining peanut allergen on the hands or in the saliva of someone who
consumed peanuts. When an individual ingests peanuts and touches or kisses someone not yet
exposed, it can cause sensitization.
At first, it seems that the results of the study demonstrate a strong association between
increased maternal consumption of peanuts during pregnancy and lactation and children who
develop peanut allergy. This inconsistency was resolved by adjusting for household peanut using
logistic regression. They concluded that maternal consumption is irrelevant, since mothers in
households with high peanut consumption are more probable to eat peanut because of its
accessibility.
One group of children had high levels of environmental exposure and consumption of
peanuts during infancy, yet they were tolerant to peanuts. This data supports the hypothesis that
infant oral exposure to peanuts can induce tolerance and prevent development of peanut allergy
even where there is environmental exposure as well. This study demonstrates that high levels of
environmental exposure due to household consumption increases cutaneous sensitization to
peanuts. It also refutes the original hypothesis that peanut consumption during pregnancy and
lactation causes the development of peanut allergy in infants (Fox et al, 2009).
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This theory is known as the dual-allergen exposure hypothesis. Low-dose early
environmental exposure of peanut is taken up by Langerhan’s cells in the skin which leads to
TH2 responses and release of IgE by B cells resulting in allergic sensitization. On the contrary,
early infant consumption causes TH1 and regulatory T cell responses thereby inducing tolerance.
This hypothesis reveals the connection between the presence of infant eczema and the ensuing
development of food allergy. It also explains the rates of food allergies in different parts of the
world and changes over time (Lack, 2008).

(Lack, 2008)
EARLY CONSUMPTION OF PEANUT
In order to investigate the effect of early consumption of peanut, Du Toit et al, compared
peanut allergy prevalence among Jewish children in the UK and Israel. Israeli children consume
peanut in high quantities early in life, while UK Jewish children avoid it altogether. Nonetheless,
Jewish children in the UK had a peanut allergy prevalence of more than 10-fold higher than in
Israel. Their findings imply that early and frequent high dose peanut consumption may thwart the
development of peanut allergy (Du Toit et al, 2008). Furthermore, studies suggest that people in
African and Asian countries, where the peanut allergy rate is relatively low, consume peanuts
throughout pregnancy and infancy. Conversely, in the U.S., U.K., Australia and Canada peanut
consumption is higher, yet there is a much greater prevalence of peanut allergy. This is due to the
fact that there is a lot of environmental exposure accompanied by avoidance of peanuts during
infancy (Lack, 2008).

Food allergies among allergy clinic patients
Country

Peanut allergy
(%)

Dietary practice recommendations (infant peanut
consumption)
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Country

Peanut allergy
(%)

Dietary practice recommendations (infant peanut
consumption)

United Kingdom (n =
191)

25

Avoidance

United States (n =
300)

69

Avoidance

Israel (n = 992)

2.1

High infant consumption

Philippines (n = 184)

0

High infant consumption
(Lack, 2008)

The results from these studies suggest a possibility that high levels of environmental
exposure without oral exposure can result in peanut allergy, while elevated peanut ingestion can
induce peanut tolerance. Further study is needed to investigate the validity of this hypothesis. It
is extremely difficult to differentiate between the precise effects of maternal consumption and
household peanut exposure. Moreover, there are other factors that can explain the difference in
peanut allergy prevalence between Israel and England.
First, there may be a delayed increase in Israel since the prevalence of 0.17% that Du Toit
et al recorded is a 4- fold increase from what was originally recorded by Dalal et al in 2002.
Additionally, most peanuts in Israel are boiled which decreases its allergic properties as
compared to being roasted which increases its allergenicity. Nonetheless, this promising theory is
being investigated further by the Learning Early About Peanut Allergy study through a
randomized controlled trial to assess whether early peanut consumption in high risk infants will
prevent peanut allergy more effectively than avoidance during infancy (Burks, 2009).

FUTURE THERAPIES
Most of the clinical studies being performed on peanut allergy are devoted to finding an
effective treatment to help patients with severe reactions to peanuts (de Leon et al, 2007). The
standard subcutaneous immunotherapy has been eliminated because it resulted in many adverse
reactions. Immunotherapeutic approaches to food allergy in general, have recently been
categorized as food allergen-specific and food allergen-nonspecific. Presently, there is no cure
for food allergy. The only treatment for peanut allergy is stringent avoidance of all peanut
containing products. The immunotherapeutic approaches discussed below are tentative and
require further research (Sicherer and Sampson, 2007).
SUBLINGUAL AND ORAL IMMUNOTHERAPY
Sublingual immunotherapy (SLIT) and oral immunotherapy (OIT) are both allergen
specific therapeutic approaches. Both these therapies are designed based on the theory of induced
tolerance when an antigen is presented at the oral mucosa/ gut associated lymphoid system. In
SLIT and OIT, patients are introduced to small amounts of the allergen orally and the amount is
increased over time. Although these therapies do provide desensitization for many patients on
therapy, there is no proof that induces tolerance. Furthermore, there are risks of extreme side
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effects and anaphylaxis if the patient stops therapy for 1-3 weeks and then resumes with the same
dosage (Sicherer and Sampso, 2007).
MODIFIED PROTEIN VACCINE
The engineered recombinant protein strategy is an allergen-specific method which
attempts to minimize IgE activation by mutating IgE binding sites. The three major peanut
allergens are separated to identify their allergenic epitopes/ IgE binding sites (Nowak-Wegrzyn
et al, 2009).Then, mutations are made to the peanut allergen gene which makes these sites
nonreactive to IgE. When the mutated peanut allergen is expressed, it will result in
hypoallergenic variants which can be used for immunotherapy (de Leon et al, 2007). This
method is much safer than standard subcutaneous which injected the native protein into the skin.
This approach looks very promising in murine models and human studies are being planned for
further testing (Sicherer et al, 2010).
CHINESE HERBAL MEDICINE
Li and colleagues developed a 9-herb preparation known as Food Allergy Herbal
Formula (FAHF-2), which is an allergen-nonspecific approach that prevents peanut inducedanaphylaxis (Sicherer and Sampson, 2007). In one experiment, peanut allergic mice treated with
FAHF-2 for 7 weeks were challenged 1, 3, or 5 weeks after therapy. They recorded that IgE
levels were particularly reduced by FAHF-2 and remained that way as long as 5 weeks after
therapy was completed. This result seems to be connected to the suppression of TH2 cytokines by
the FAHF-2. The full protection that FAHF-2 demonstrated was replicated in many experiments
and always showed a consistent response. This herbal formula might prove to be a valuable and
harmless treatment for peanut allergy (Srivastava et al, 2005)
ADDITIONAL IMMUNOTHERAPEUTIC METHODS
Other types of food allergen-specific therapies include cytokine-modulated
immunotherapy, immunostimulatory sequence-conjugated protein-modulated immunotherapy,
plasmid DNA-based immunotherapy, and allergen peptide immunotherapy. All these treatments
try to lessen the TH2 response or induce tolerance to a specific food allergen (Burks, 2008). One
study shows that similar proteins found in soybeans can be used for immunotherapy to
desensitize peanut allergic mice (Pons et al, 2004). Another allergen non-specific approach is
anti IgE therapy which does not cure the allergy but rather reduces fatal reactions in patients
(Burks, 2008). The responses to this therapy turned out to be inconsistent, and this method has
been suspended due to safety issues (Nowak-Wegrzyn et al, 2009).
Selected immunotherapeutic strategies:
Therapy

Immune rationale

Benefits

Observations to date

Standard
subcutaneous
immunotherapy
(native allergens)

Antigen presentation Proved for venom and
Primarily avoided for
in nonmucosal site
respiratory allergy,
risk of anaphylaxis
results in TH1 skewing possible benefit (pollen) (eg, peanut)
for oral allergy
syndrome

Sublingual/OIT

Antigen presentation
to mucosal site
provides
desensitization and

Natural foods, reduced
risk of systemic
anaphylaxis compared
with injections

Mounting evidence
for desensitization
and relative safety;
unclear effect on
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Therapy

Immune rationale

Benefits

might induce tolerance
Modified protein
vaccine

Reduced IgE
activation by mutation
of IgE-binding
epitopes

Observations to date
tolerance

A safer form of
Murine models show
immunotherapy
promise, human
compared with injection studies are planned
of native protein

Peptide vaccine
Peptides are less likely No requirement for IgE
(overlapping peptides) to cross-link IgE,
epitope
avoiding mast cell
mapping/mutation
activation

Limited

Conjugation of
immune stimulatory
sequences to allergen
and additional
adjuvant methods

Enhance TH2 response Increased efficacy,
Preclinical studies
by activating innate
possibly improved safety
immune receptors
(using specific
sequences or whole
bacteria)

Plasmid DNAencoded vaccines

Endogenous
Possible 1-dose
production of allergen treatment
might result in
tolerance

Murine models
reveal strain-specific
response

Anti-IgE antibodies

Targeted toward Fc
portion of antibody,
can inactivate IgE with
reduced risk for
activating mast cells

Not food specific Some
response in eosinophilic
gastroenteropathy (pilot
study)

Preliminary study
showed improved
threshold overall but
did not show uniform
protection

Chinese herbal
medicine

Mechanism unknown

Not food specific

Murine models show
efficacy Human
safety studies are
underway

Might allow directed
interruption of
inflammatory processes
without need for food
restriction

Preliminary study
shows benefit for
eosinophilic
esophagitis.

Cytokine/antiTo interrupt
cytokine (eg, anti–IL- inflammatory signals
5)

(Sicherer et al, 2010)
CONCLUSION
It has been proven that peanut allergy is becoming increasingly prevalent and poses a
health threat worldwide, specifically in developed countries. In peanut allergic individuals, the
exposure of peanut allergens via the gut, skin, or air can lead to clinical symptoms ranging from
mild skin conditions to fatal anaphylaxis. Much research has been done to investigate the
immunologic, environmental, and genetic affects on the development of peanut allergy. Studies
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show that peanut proteins undergo the Maillard reaction during thermal processing, thus
increasing the allergenicity of peanuts. Furthermore, roasting uses elevated temperatures that
strengthen the allergic properties of peanut proteins by causing permanent changes in its
structure. Another study suggests that Ara h 2 purified from peanuts acts as a trypsin inhibitor
and roasting increases the trypsin inhibitory activity.
Some studies propose that genetic factors are linked to the development of peanut allergy,
while the vitamin D hypotheses suggest that either increased or decreased levels of vitamin D
leads to increasing allergy prevalence. Furthermore, it was originally thought that avoidance of
peanuts during pregnancy and lactation can prevent development of peanut allergy in the
fetus/infant. However, this was disproven, and the dual allergen exposure hypothesis, which
states that low-dose early environmental exposure increases the probability of developing a
peanut allergy, is the newest proposition. There are some allergen specific and allergen
nonspecific therapies available to reduce fatal peanut allergic reactions. Research is being done
to provide a therapy that induces tolerance to peanut without adverse side effects.
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